SAN DIEGO, CA--(Marketwire - September 15, 2009) - ChemDiv Inc. of San Diego, and iDialog
(Intellektualniy Dialog) of Yaroslavl, Russia, announced today the
successful completion of a pre-clinical development and the subsequent
nomination of ID-12 as lead clinical development candidate for the
treatment of chronic hepatitis C. This novel small molecule
orally-bioavailable inhibitor of hepatitis C virus (HCV) blocks early stage
of viral infection.
Vadim Bichko, Ph.D, ChemDiv's Vice President of Virology, stated: "We are
very encouraged by the safety, potency, PK profile, and novel molecular
mechanism of action, exhibited by iDialog's HCV inhibitor in the
preclinical studies. We are quite excited by the ability of ID-12 to
prevent spread of viral infection through cell-cell contact, which makes it
superior to the neutralizing antibodies and other viral entry inhibitors.
This mechanism of action is complimentary to that of other classes of HCV
inhibitors currently on the market, or in late stage clinical development.
Thus, ID-12 is a potentially important component of therapeutic cocktails
for chronic hepatitis C."
The Phase I study is scheduled to begin in Q4 2009, and will be conducted
in Russia. The objectives of the trial include assessment of safety,
tolerability and pharmacokinetics. iDialog plans to present first clinical
results at a scientific meeting in the second half of 2010. ChemDiv will
continue supporting R&D programs of iDialog, including Proof of Concept
Studies in man, through its Chemical Diversity Research Institute in
Prof. Dr. Mikhail Dorogov, Director General of iDialog, confirmed: "We are
happy that our discovery effort over last 3 years resulted in advancement
of the candidate molecule to clinic. We shall strive in developing a
successful new therapy for treatment of large population of hepatitis C
patients worldwide. With its current financing iDialog is planning to
complete the early development program to obtain clinical Proof of Concept.
We are actively exploring options, which will allow us to accelerate the
program with maximizing our shareholder's return on investment. We believe
our approach is matching to innovative models of early partnering,
co-development an co-investment established by pharma and investment
community in the recent past."
About Hepatitis C
The U.S. Center for Disease Control and Prevention estimate that about 4.1
million persons in the United States have been infected with HCV, and 3.2
million of these people are chronic carriers. Russian Ministry of Health
and Social Development estimates that over 7 million people in Russia have
been infected with various types of Hepatitis and 2 million of them,
ChemDiv Inc. (Chemical Diversity) is a global contract research
organization accelerating external discovery and development of novel
therapies through comprehensive Discovery Outsource services, including
discovery biology, medicinal and synthetic chemistry, pre-clinical and
iDialog was established in 2006 as an innovative biopharma start up. It
received over USD$3M of seed investment from Torrey Pines Investment in
2007 and subsequently won the research partnership award of over USD$3
from the Russian Federal Agency of Science and Innovation for development
of novel anti-infective agents to match unmet needs in Russia. iDialog
conducted and continues the broad program to discover novel therapies for
Tuberculosis, hepatitis C and Influenza, in partnership with Moscow State
University and other academic organizations. In 2008 iDialog established
the R&D collaboration with ChemDiv's Chemical Diversity Research Institute
for discovery and development of novel small molecule anti-infective
agents, which is extended to 2011.